SHTPY (Schott Pharma AG KGaA) Retained Earnings: $0 Mil (As of Mar. 2026)


SHTPY Schott Pharma AG & CO KGaA SHTPY
64 GF Score
Price $4.37
GF Value $7.02
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA Retained Earnings?

Schott Pharma AG KGaA SHTPY -42.88% 64 Retained Earnings is $0 Mil as of Mar. 2026. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Schott Pharma AG KGaA's retained earnings for the quarter that ended in Mar. 2026 was $0 Mil.


Schott Pharma AG KGaA  (OTCPK:SHTPY) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Schott Pharma AG KGaA Retained Earnings Historical Data

* Premium members only.

The historical data trend for Schott Pharma AG KGaA's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA Retained Earnings Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Retained Earnings
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHTPY
64GF Score
Schott Pharma AG & CO KGaA SHTPY
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Schott Pharma AG KGaA Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $0 Mil mean?
Schott Pharma AG KGaA (SHTPY) has a Retained Earnings of $0 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Schott Pharma AG KGaA and its competitors.
Is Schott Pharma AG KGaA's Retained Earnings too high?
Schott Pharma AG KGaA's current Retained Earnings is $0 Mil. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Retained Earnings compare to ISRG and BDX?
Schott Pharma AG KGaA's Retained Earnings of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Schott Pharma AG KGaA and its competitors. Schott Pharma AG KGaA's current Retained Earnings is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Retained Earnings of $0 Mil. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current Retained Earnings is $0 Mil. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Retained Earnings is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.

Key valuation signals for SHTPY:

  • Retained Earnings: $0 Mil
  • GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Schott Pharma AG KGaA Business Description

Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score

Get the complete analysis for SHTPY

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.37
Price
$7.02
GF Value